IsomAb is pioneering the development of isoform-specific antibodies, and through a comprehensive bioinformatics and knowledge-based platform, they have pinpointed ISM-001. This antibody demonstrates specific inhibition of the Vascular Endothelial Growth Factor-A (VEGF-A) isoform, VEGF-A165b. With over two decades of research by our founders supporting this discovery, the evidence suggests that lowering serum levels of VEGF-A16...
IsomAb is pioneering the development of isoform-specific antibodies, and through a comprehensive bioinformatics and knowledge-based platform, they have pinpointed ISM-001. This antibody demonstrates specific inhibition of the Vascular Endothelial Growth Factor-A (VEGF-A) isoform, VEGF-A165b. With over two decades of research by our founders supporting this discovery, the evidence suggests that lowering serum levels of VEGF-A165b is crucial for promoting new blood vessel formation in patients with ischemic disease.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.